

# Multiple Sclerosis Market Poised for Significant Growth by 2034, Predicts DelveInsight

*DelveInsight's report on Multiple Sclerosis comprehensively analyzes the epidemiology and market trends across the 7MM.*

LAS VEGAS , NV, UNITED STATES, January 24, 2025 /EINPresswire.com/ -- DelveInsight's "Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

To Know in detail about the Multiple Sclerosis market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: [Multiple Sclerosis Market Forecast](#)

Some of the key facts of the Multiple Sclerosis Market Report:

- The Multiple Sclerosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In 2023, the total prevalent cases of multiple sclerosis in the United States were estimated at 728,000. These figures are expected to change significantly by 2034.
- In 2023, gender-based segmentation of multiple sclerosis cases in Germany showed around 61,000 cases in males and 150,000 cases in females.
- In the UK, when categorized by phenotype, a notable disparity in the prevalence of multiple sclerosis was observed, with a higher incidence of relapsing-remitting multiple sclerosis (RRMS) compared to Clinically Isolated Syndrome, Secondary Progressive Multiple Sclerosis (SPMS), and Primary Progressive Multiple Sclerosis (PPMS). Approximately 80,000 cases of RRMS were recorded in 2023, and these numbers are expected to fluctuate further through 2034.
- In France, about 79,000 prevalent cases of multiple sclerosis were recorded in 2023, with expected changes by 2034.
- The market size for multiple sclerosis in the U.S. was approximately USD 20,559 million in 2023, with significant growth expected by 2034 at a high compound annual growth rate (CAGR) throughout the study period (2020–2034).
- The U.S. accounts for the largest share of the multiple sclerosis market, comprising approximately 80% of the total 7MM market size.
- Emerging therapies such as CNM-Au8 and others have the potential to create significant shifts

in the multiple sclerosis market.

- In December 2024, Sanofi announced that the U.S. FDA granted Breakthrough Therapy designation to tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS), following positive results from the HERCULES phase 3 study, showing potential in delaying disability progression.
- In October 2024, SetPoint Medical received Investigational Device Exemption (IDE) approval from the FDA to study its proprietary neuroimmune modulation platform in individuals with relapsing-remitting multiple sclerosis (RRMS).
- In September 2024, Roche announced FDA approval for OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) for relapsing and primary progressive multiple sclerosis (MS). This first subcutaneous injection for both forms of MS is administered by a healthcare professional twice a year in about 10 minutes, offering expanded treatment options.
- Emerging therapies include CNM-Au8, IMS001, Fenebrutinib (GDC-0853, RG7845), and others.
- Leading companies in the multiple sclerosis market include Immune Response BioPharma, Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, and others.
- The Multiple Sclerosis market is expected to experience substantial growth, driven by the rising demand for effective therapies, advances in genetic research, and ongoing clinical trials focused on improving patient outcomes for this rare neurodegenerative disease.

## Multiple Sclerosis Overview

Multiple Sclerosis (MS) is an unpredictable autoimmune disorder that impacts the central nervous system. In MS, the body's immune system generates cells and antibodies that attack myelin, the fatty substance that insulates and protects nerve fibers. This condition is typically marked by episodes of neurological impairment followed by periods of remission.

The destruction of myelin leads to the formation of scar tissue (sclerosis), and in many cases, the nerve fibers themselves are also damaged. When the myelin sheath or nerve fibers are harmed, the transmission of nerve impulses to and from the brain and spinal cord becomes distorted or disrupted.

Get a Free sample for the Multiple Sclerosis Market Report:

[https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=jpr](https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr)

## Multiple Sclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Multiple Sclerosis Epidemiology Segmentation:

The Multiple Sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Total Prevalent cases of Multiple Sclerosis
- Gender-specific diagnosed prevalent cases of Multiple Sclerosis
- Phenotype-specific diagnosed prevalent cases of Multiple Sclerosis
- Age-specific diagnosed prevalent cases of Multiple Sclerosis

Download the report to understand which factors are driving Multiple Sclerosis epidemiology trends @ [Multiple Sclerosis Epidemiology Forecast](#)

### Multiple Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to be launched during the study period. The analysis covers the Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

### Multiple Sclerosis Therapies and Key Companies

- CNM-Au8: Clene Nanomedicine
- IMS001: ImStem Biotechnology
- Fenebrutinib (GDC-0853, RG7845): Hoffmann-La Roche

### Multiple Sclerosis Market Strengths

- With the United States accounting for 80% of the 7MM multiple sclerosis market and many prevalent cases, the market is poised for continued growth, offering substantial revenue opportunities for pharmaceutical companies and stakeholders in the MS treatment space.
- The approval of breakthrough therapies such as tolebrutinib and OCREVUS ZUNOVO™, along with emerging treatments like CNM-Au8, promises to expand and diversify treatment options for MS patients, addressing various forms and subtypes of the disease.

### Multiple Sclerosis Market Opportunities

- With the growing pipeline of emerging therapies, including CNM-Au8 and others, there is an opportunity to introduce new and more effective treatments, especially for underserved subtypes like secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).
- Rising awareness and improved diagnostic capabilities could lead to earlier diagnosis and

better management of multiple sclerosis, creating opportunities for preventive and therapeutic interventions across global markets.

### Scope of the Multiple Sclerosis Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Multiple Sclerosis Companies: Immune Response BioPharma, Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, and others.
- Key Multiple Sclerosis Therapies: CNM-Au8, IMS001, Fenebrutinib (GDC-0853, RG7845), and others.
- Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies
- Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Multiple Sclerosis Unmet Needs, KOL’s views, Analyst’s views, Multiple Sclerosis Market Access and Reimbursement

To learn more about Multiple Sclerosis companies working in the treatment market, visit @ [Multiple Sclerosis Clinical Trials and Therapeutic Assessment](#)

### Table of Contents

1. Multiple Sclerosis Market Report Introduction
2. Executive Summary for Multiple Sclerosis
3. SWOT analysis of Multiple Sclerosis
4. Multiple Sclerosis Patient Share (%) Overview at a Glance
5. Multiple Sclerosis Market Overview at a Glance
6. Multiple Sclerosis Disease Background and Overview
7. Multiple Sclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Multiple Sclerosis
9. Multiple Sclerosis Current Treatment and Medical Practices
10. Multiple Sclerosis Unmet Needs
11. Multiple Sclerosis Emerging Therapies
12. Multiple Sclerosis Market Outlook
13. Country-Wise Multiple Sclerosis Market Analysis (2020–2034)
14. Multiple Sclerosis Market Access and Reimbursement of Therapies
15. Multiple Sclerosis Market Drivers
16. Multiple Sclerosis Market Barriers
17. Multiple Sclerosis Appendix
18. Multiple Sclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

#### About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/779955787>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.